Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Dicerna Pharmaceutic
(NQ:
DRNA
)
24.64
USD
UNCHANGED
Streaming Delayed Price
Updated: 5:01 PM EST, Jan 22, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Dicerna Pharmaceutic
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Dicerna to Participate in the H.C. Wainwright Virtual BioConnect Conference
January 05, 2021
Dicerna announced that Doug Fambrough will participate in two events at the H.C. Wainwright Virtual BioConnect Conference taking place Jan. 11-14.
From
Business Wire News Releases
Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement
January 05, 2021
Dicerna announced that Novo Nordisk has nominated its first candidate for development under the existing agreement between the two companies.
From
Business Wire News Releases
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2021
Dicerna announced the Company approved the grant of inducement stock options of common stock and restricted stock units among three new employees.
From
Business Wire News Releases
Dicerna Announces Enrollment Completion of PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria
January 04, 2021
Dicerna today announced the enrollment completion of the PHYOX™2 pivotal trial of nedosiran for the treatment of primary hyperoxaluria.
From
Business Wire News Releases
PBE's Holdings Imply 11% Gain Potential
December 30, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
First Week of DRNA February 2021 Options Trading
December 18, 2020
Investors in Dicerna Pharmaceuticals Inc (DRNA) saw new options become available this week, for the February 2021 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the...
Tags
Stocks
From
Market News Video
Stocks Generating Improved Relative Strength: Dicerna Pharmaceuticals
December 15, 2020
Dicerna Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
From
Investor's Business Daily
Notable Friday Option Activity: MAXR, DRNA, OPCH
December 11, 2020
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Maxar Technologies Inc (MAXR), where a total volume of 5,451 contracts has been...
Tags
Stocks
From
Market News Video
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2020
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among six new employees.
From
Business Wire News Releases
Dicerna Pharmaceuticals Trying To Close In On Key Technical Benchmark
November 30, 2020
Dicerna Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
From
Investor's Business Daily
Dicerna Announces Positive Updated Data From Phase 1 Trial of RG6346 for Treatment of Chronic Hepatitis B Virus (HBV) Infection at AASLD’s The Liver Meeting® Digital Experience™ 2020
November 16, 2020
Dicerna announced positive updated Phase 1 data on its investigational GalXC™ RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV).
From
Business Wire News Releases
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for First GalXC™ RNAi Candidate Under Companies’ Global Research Collaboration and Licensing Agreement
November 16, 2020
Dicerna announced FDA acceptance of the IND Application filed by Lilly for LY3561774, clinical-stage candidate to emerge from their collaboration.
From
Business Wire News Releases
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
November 15, 2020
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market. The ...
Tags
ALKS
LCTX
Small Cap
From
Benzinga
Analysts Anticipate ESML Will Reach $33
November 13, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
Dicerna to Participate in Upcoming Investor Conferences
November 11, 2020
Dicerna announced that Douglas M. Fambrough, Ph.D., president and CEO, will be participating in fireside chats at two upcoming investor conferences.
From
Business Wire News Releases
Dicerna Presents New Nonclinical Research Highlighting the Application of its RNAi Technology in Extrahepatic Tissues at TIDES Europe 2020
November 10, 2020
Dicerna will present an update on the Company’s early-stage development of extrahepatic RNAi therapeutics at TIDES Europe 2020.
From
Business Wire News Releases
Dicerna Announces Third Quarter 2020 Financial Results and Provides a Business Update
November 05, 2020
Dicerna today reported its financial results for the third quarter ended Sep. 30, 2020.
From
Business Wire News Releases
WaterMill Asset Management Sends Letter to Ziopharm Oncology Shareholders
November 05, 2020
WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of...
From
Business Wire News Releases
The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping
November 05, 2020
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Tags
NBRV
GERN
Earnings
From
Benzinga
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2020
Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among nine new employees.
From
Business Wire News Releases
Dicerna Announces Updated Phase 1 Data on RG6346 Investigational Treatment for Chronic Hepatitis B Virus to be Presented in Late-Breaking Session at AASLD’s The Liver Meeting® Digital Experience™ 2020
November 01, 2020
Dicerna will present updated data related to RG6346, an RNAi investigational therapy, at The Liver Meeting® Digital Experience™ 2020.
From
Business Wire News Releases
The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings
November 01, 2020
Biotech stocks continued to sway to the tunes of the broader market in the week ended Oct. 30, which succumbed to geopolitical and ...
Tags
ICUI
BDSI
CATB
From
Benzinga
Dicerna to Report Third Quarter 2020 Financial Results on November 5, 2020
October 29, 2020
Dicerna announced that it will release its Q3 2020 financial results and will provide a general business update on Thursday, Nov. 5.
From
Business Wire News Releases
IBD Rating Upgrades: Dicerna Pharmaceuticals Shows Improved Relative Price Strength
October 29, 2020
A Relative Strength Rating upgrade for Dicerna Pharmaceuticals shows improving technical performance. Will it continue?
From
Investor's Business Daily
Dicerna Presents Positive New Interim Data From PHYOX™3 Long-Term, Open-Label Extension Study of Nedosiran for Treatment of Primary Hyperoxaluria (PH)
October 22, 2020
Dicerna announced positive new interim data from its ongoing PHYOX3 open-label trial of nedosiran, an investigational therapy for PH1, PH2 and PH3.
From
Business Wire News Releases
Dicerna Pharmaceuticals (DRNA) Shares Cross Above 200 DMA
October 15, 2020
In trading on Thursday, shares of Dicerna Pharmaceuticals Inc (DRNA) crossed above their 200 day moving average of $20.51, changing hands as high as $20.74 per share. Dicerna Pharmaceuticals Inc shares...
Tags
Stocks
From
Market News Video
Vertex Tumbles As It Stops Testing On Protein Deficiency Treatment
October 15, 2020
Shares of Vertex plunged after hours Wednesday after the company announced it planned to stop testing on a drug designed to treat protein deficiencies. VRTX stock fell by double digits.
From
Investor's Business Daily
Noteworthy Thursday Option Activity: X, UNH, DRNA
October 15, 2020
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in United States Steel Corp. (X), where a total volume of 59,397 contracts has been...
Tags
Stocks
From
Market News Video
Dicerna to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
October 13, 2020
Dicerna announced that Doug Fambrough will participate in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on Tuesday, Oct. 20.
From
Business Wire News Releases
Implied PBE Analyst Target Price: $75
October 13, 2020
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.